Advocacy

Advocacy News

ASAM and NJSAM Submit Letters of Support for Legislation Requiring State Insurers to Cover Buprenorphine Costs and Prohibit Utilization Controls

July 7, 2017

Letter of Support for A4138

Letter of Support for S1051

 

ASAM and the New Jersey Society of Addiction Medicine (NJSAM) submitted letters of support with recommended revision for A4138 and S1051, legislation that would require state insurance providers to cover the costs of buprenorphine and prohibit utilization controls.